Camp4 Therapeutics (CAMP) has an average rating of buy and mean price target of $7.79, according to analysts polled by FactSet.
What else is happening in Research?
Research
Barclays Downgrades Nuvalent to Equalweight From Overweight, $124 Price Target
Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.Price: $123.08, Change: $+34.59, Percent Change: +39.08%
$NUVL
Research
Raymond James Downgrades Nuvalent to Market Perform From Outperform
Nuvalent (NUVL) has an average rating of overweight and mean price target of $138.81, according to analysts polled by FactSet.Price: $122.87, Change: $+34.38, Percent Change: +38.85%
$NUVL
Research
Wells Fargo Downgrades Nuvalent to Equalweight From Overweight, Adjusts Price Target to $124 From $116
Nuvalent (NUVL) has an average rating of overweight and mean price target of $141.22, according to analysts polled by FactSet.
$NUVL